Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

(2021) Ludwig Kappos et al.   JAMA Neurology

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis

(2021) Tim Spelman et al.   JAMA Neurology

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

(2021) Steve Simpson-Yap et al.   NEUROLOGY

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis

(2019) Justin M. Honce et al.   NEUROLOGY

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

(2019) Katharine Harding et al.   JAMA Neurology

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis

(2019) M. Boremalm et al.   EUROPEAN JOURNAL OF NEUROLOGY

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?

(2018) S. G. Berntsson et al.   ACTA NEUROLOGICA SCANDINAVICA

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

(2018) Mathias Granqvist et al.   JAMA Neurology

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

(2016) M. Vågberg et al.   ACTA NEUROLOGICA SCANDINAVICA

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

(2016) Pierre de Flon et al.   NEUROLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

(2015) D. M. Hartung et al.   NEUROLOGY

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE